Dr Aditya Shreenivas
Dr Aditya Shreenivas
Oncology
MD MS Haematology Medical Oncology (USA)
Registered Number –
Milwaukee
Experience – 15 years
Language - English, Hindi
Dr. Shreenivas is an assistant professor of medicine, in the division of Haematology and Medical Oncology at the Medical college of Wisconsin, Milwaukee. He specializes in Head & Neck and Gastrointestinal Medical Oncology. He did his residency in internal medicine at Bronx Lebanon Medical center, New York and fellowship in Hematology& Oncology at Mt. Sinai Medical Center, Icahn school of Medicine, New York. Dr. Shreenivas also has a master in clinical research from the Icahn school of Medicine, New York. While undergoing his masters and fellowship training in Hematology/Oncology at the Mount Sinai Hospital, he was recognized with the best master’s thesis award in the year 2018.
Dr. Shreenivas is board certified in internal medicine, hematology, and medical oncology. In addition to a focus on treating rare tumors, he provides multidisciplinary care in the fields of head and neck and gastrointestinal cancers. Dr. Shreenivas is actively involved in clinical research.
Dr. Shreenivas is board certified in internal medicine, hematology, and medical oncology. In addition to a focus on treating rare tumors, he provides multidisciplinary care in the fields of head and neck and gastrointestinal cancers. Dr. Shreenivas is actively involved in clinical research.
Education and Training
Doctor of Medicine – JSS Medical College – Mysore, Karnataka, (2010) Residency in Internal Medicine – Bronx Lebanon Hospital Center – Bronx, NY (2012-2015) Fellowship in Hematology & Oncology – Icahn School of Medicine at Mount Sinai – New York, NY (2015-2018) Master’s in Clinical Research – Icahn School of Medicine at Mount Sinai – New York, NY (2018)x
- Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review. (Sheth H, Limaye S, Kumar P, Shreenivas A.) J Cancer Res Clin Oncol. 2023 Jul;149(8):4915-4923 PMID: 36307559 SCOPUS ID: 2-s2.0-85140994451 10/29/2022
- Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer. (Matoska T, Banerjee A, Shreenivas A, Jurkowski L, Shukla ME, Gore EM, Linsky P, Gasparri M, George B, Johnstone C, Johnstone D, Puckett LL.) Cancers (Basel). 2023 Apr 28;15(9) PMID: 37173988 PMCID: PMC10177457 SCOPUS ID: 2-s2.085159164697 05/13/2023
- Genomic profiling and precision medicine in complex ameloblastoma. (Gates JC, Clark AP, Cherkas E, Shreenivas AV, Kraus D, Danzinger N, Huang RSP, Johnson J, Ross JS.) Head Neck. 2023 Apr;45(4):816-826 PMID: 36645099 SCOPUS ID: 2-s2.0-85146321999 01/17/2023
- Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. (Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC.) Blood. 2023 Jan 30 PMID: 36720090 SCOPUS ID: 2-s2.0-85150860589 02/01/2023
- Addendum: Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy. (Nagarkar R, Patil D, Limaye S, Devhare P, Ghaisas A, Srivastava N, Apurwa S, Patil S, John J, Raazi Z, Shreenivas A, Sambath J, Srinivasan A, Kumar P, Akolkar D, Datar R.) Oncotarget. 2022 Nov 02;13:1215 PMID: 36342460 PMCID: PMC9629807 11/08/2022
- Carcinoma of unknown primary: Molecular tumor board-based therapy. (Shreenivas AV, Kato S, Hu J, Skefos C, Sicklick J, Kurzrock R.) CA Cancer J Clin. 2022 Nov;72(6):510-523 PMID: 36006378 PMCID: PMC10180180 SCOPUS ID: 2-s2.085137039668 08/26/2022
- Chronic stress promotes an immunologic inflammatory state and head and neck cancer growth in a humanized murine model. (Zenga J, Awan MJ, Frei A, Petrie E, Sharma GP, Shreenivas A, Shukla M, Himburg HA.) Head Neck. 2022 Jun;44(6):1324-1334 PMID: 35261119 PMCID: PMC9081149 SCOPUS ID: 2-s2.0-85125920861 03/10/2022
- Reply to S. Cavalieri et al. (Limaye S, Kumar P, Datar R, Shreenivas A.) JCO Precis Oncol. 2021 Nov;5:1528-1529 PMID: 34994641 01/08/2022
- Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. (Kamgar M, Chakrabarti S, Shreenivas A, George B.) Surg Oncol Clin N Am. 2021 Oct;30(4):673-691 PMID: 34511189 SCOPUS ID: 2-s2.0-85111041414 09/14/2021
- Utility of circulating tumor DNA (ctDNA)-based tumor genomic profiling in previously treated patients with advanced gastrointestinal (GI) cancer (Ronald Cox, BS 1 , Edward McKenna, MD 1 , Marie Parish, PharmD, BCPS, BCOP 1 , Bicky Thapa, MD 1 , Aditya Shreenivas, MD 1 , Sakti Chakrabarti, MD 1.) International Journal of Cancer Care and Delivery. 10/01/2021
- A closer look at 30 day hospital readmissions after head and neck cancer surgery. (Puccia R, Ramamurthi A, Grond SE, McCormick C, Ng A, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz C, Wong S, Shreenivas A, Zenga J.) Am J Otolaryngol. 2021;42(5):103146 PMID: 34171529 SCOPUS ID: 2-s2.0-85108366965 06/26/2021
- Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report. (Sheth H, Kumar P, Shreenivas A, Sambath J, Pragya R, Madre C, Athikari N, Khandare H, Peshattiwar V, Datar R, Limaye S.) JCO Precis Oncol. 2021;5 PMID: 34036229 PMCID: PMC8140801 05/27/2021
